FDA 483 - Biomat USA Inc - November 06, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Biomat USA Inc in Killeen, TX, from November 3-6, 2025, revealed a significant failure to perform thorough investigations into unexplained discrepancies. Specifically, the firm's CAPA investigations did not adequately address an employee's deliberate entry of false quality control results for donor hematocrit testing, nor did they fully correct repeated failures to record cannula lot numbers for collected source plasma. These issues indicate serious deficiencies in the firm's quality system and investigation processes, potentially impacting donor eligibility and product safety.
ID · 607903a9-d858-411f-be61-0fa745ed6f6e